The New York Times is reporting Boehringer Ingelheim, makers of the blood-thinning drug Pradaxa, were so worried that an internal research paper would damage drug sales that some employees not only pressured the author to revise it, but suggested it should be quashed altogether, according to newly unsealed legal documents. The documents were made public last week by a federal …